A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Patients With Major Depressive Disorder With an Inadequate Response to Current Antidepressant Treatment

The purpose of this study is to evaluate the safety, tolerability, and efficacy of TS-121 as an adjunctive treatment for patients with major depressive disorder with an inadequate response to current antidepressant Treatment (SSRI, SNRI or bupropion).

开始日期2017-07-03

申办/合作机构

Taisho Pharmaceutical R&D, Inc.

NCT02448212

/ Completed临床1期

A Phase 1 Receptor Occupancy Study Using Positron Emission Tomography to Investigate Novel Ligand [11C]TASP0410699 Alone and Following Single Oral Dose Administrations of TS-121 in Healthy Adult (Male) Subjects

The purpose of this study is to evaluate the binding of a novel tracer, [11C]TASP0410699, using Positron Emission Tomography (PET) scans with or without dosing of TS-121

开始日期2015-05-01

申办/合作机构

Taisho Pharmaceutical R&D, Inc.

[+1]

100 项与 Brezivaptan 相关的临床结果

登录后查看更多信息

100 项与 Brezivaptan 相关的转化医学

登录后查看更多信息

100 项与 Brezivaptan 相关的专利（医药）

登录后查看更多信息

项与 Brezivaptan 相关的文献（医药）

2022-04-01·Journal of Nuclear Medicine1区 · 医学

Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer ¹¹C-TASP699

1区 · 医学

Article

作者: Ozaki, Satoshi ; Huang, Yiyun ; Nishino, Izumi ; Nabulsi, Nabeel B ; Ropchan, Jim ; Lin, Shu-Fei ; Suhara, Tetsuya ; Sabia, Helene ; Henry, Shannan ; Labaree, David ; Gao, Hong ; Matuskey, David ; Carson, Richard E ; Zhang, Ming-Rong ; Naganawa, Mika ; Pracitto, Richard

Arginine vasopressin is a hormone that is synthesized mainly in the hypothalamus and stored in the posterior pituitary. Receptors for vasopressin are categorized into at least 3 subtypes (V_1A, V_1B, and V₂). Among these subtypes, the V_1B receptor (V_1BR), highly expressed in the pituitary, is a primary regulator of hypothalamic-pituitary-adrenal axis activity and thus a potential target for treatment of neuropsychiatric disorders such as depression and anxiety. N-tert-butyl-2-[2-(6-methoxypyridine-2-yl)-6-[3-(morpholin-4-yl)propoxy]-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl]acetamide (TASP699) is a novel PET radiotracer with high affinity and selectivity for V_1BR. The purpose of this study was to characterize the pharmacokinetic and binding profiles of ¹¹C-TASP699 in humans and determine its utility in an occupancy study of a novel V_1BR antagonist, TS-121. Methods: Six healthy subjects were scanned twice with ¹¹C-TASP699 to determine the most appropriate kinetic model for analysis of imaging data and test-retest reproducibility of outcome measures. Nine healthy subjects were scanned before and after administration of TS-121 (active component: THY1773) to assess V_1BR occupancy. Metabolite-corrected arterial input functions were obtained. Pituitary time-activity curves were analyzed with 1- and 2-tissue-compartment (1TC and 2TC, respectively) models and multilinear analysis 1 (MA1) to calculate distribution volume (V _T). Relative test-retest variability (TRV) and absolute TRV were calculated. Since no brain region could be used as a reference region, percentage change in V _T after TS-121 administration was computed to assess its receptor occupancy and correlate with plasma concentrations of the drug. Results: ¹¹C-TASP699 showed high uptake in the pituitary and no uptake in any brain region. The 2TC model provided better fits than the 1TC model. Because the MA1 V _T estimates were similar to the 2TC V _T estimates, MA1 was the model of choice. The TRV of V _T was good (TRV, -2% ± 14%; absolute TRV, 11%). THY1773 reduced V _T in a dose-dependent fashion, with a half-maximal inhibitory concentration of 177 ± 52 ng/mL in plasma concentration. There were no adverse events resulting in discontinuation from the study. Conclusion: ¹¹C-TASP699 was shown to display appropriate kinetics in humans, with substantial specific binding and good reproducibility of V _T Therefore, this tracer is suitable for measurement of V_1BR in the human pituitary and the V_1BR occupancy of TS-121, a novel V_1BR antagonist.

2021-07-14·International Journal of Neuropsychopharmacology2区 · 医学

Vasopressin V1B Receptor Antagonists as Potential Antidepressants

2区 · 医学

ReviewOA

作者: Chaki, Shigeyuki

AbstractAccumulating evidence shows that certain populations of depressed patients have impaired hypothalamus-pituitary-adrenal (HPA) axis function. Arginine-vasopressin (AVP) is one of the primary factors in HPA axis regulation under stress situations, and AVP and its receptor subtype (V1B receptor) play a pivotal role in HPA axis abnormalities observed in depression. Based on this hypothesis, several non-peptide V1B receptor antagonists have been synthesized, and the efficacies of some V1B receptor antagonists have been investigated in both animals and humans. V1B receptor antagonists exert antidepressant-like effects in several animal models at doses that attenuate the hyperactivity of the HPA axis, and some of their detailed mechanisms have been delineated. These results obtained in animal models were, at least partly, reproduced in clinical trials. At least 2 V1B receptor antagonists (TS-121 and ABT-436) showed tendencies to reduce the depression scores of patients with major depressive disorder at doses that attenuate HPA axis hyperactivity or block the pituitary V1B receptor. Importantly, TS-121 showed a clearer efficacy for patients with higher basal cortisol levels than for those with lower basal cortisol levels, which was consistent with the hypothesis that V1B receptor antagonists may be more effective for patients with HPA axis hyperactivity. Therefore, V1B receptor antagonists are promising approaches for the treatment of depression involving HPA axis impairment such as depression.

2021-05-01·Biopharmaceutics & Drug Disposition4区 · 医学

Prediction of a clinically effective dose of THY1773, a novel V_1Breceptor antagonist, based on preclinical data

4区 · 医学

Article

作者: Mizuno‐Yasuhira, Akiko ; Endo, Hiromi ; Sabia, Helene D. ; Inatani, Shoko ; Kamiya, Makoto ; Nishino, Izumi

AbstractTHY1773 is a novel arginine vasopressin 1B (V1B) receptor antagonist that is under development as an oral drug for the treatment of major depressive disorder (MDD). Here we report our strategy to predict a clinically effective dose of THY1773 for MDD in the preclinical stage, and discuss the important insights gained by retrospective analysis of prediction accuracy. To predict human pharmacokinetic (PK) parameters, several extrapolation methods from animal or in vitro data to humans were investigated. The fu correction intercept method and two‐species‐based allometry were used to extrapolate clearance from rats and dogs to humans. The physiologically based pharmacokinetics (PBPK)/receptor occupancy (RO) model was developed by linking free plasma concentration with pituitary V1B RO by the Emax model. As a result, the predicted clinically effective dose of THY1773 associated with 50% V1B RO was low enough (10 mg/day, or at maximum 110 mg/day) to warrant entering phase 1 clinical trials. In the phase 1 single ascending dose study, TS‐121 capsule (active ingredient: THY1773) showed favorable PKs for THY1773 as expected, and in the separately conducted phase 1 RO study using positron emission tomography, the observed pituitary V1B RO was comparable to our prediction. Retrospective analysis of the prediction accuracy suggested that the prediction methods considering plasma protein binding, and avoiding having to apply unknown scaling factors obtained in animals to humans, would lead to better prediction. Selecting mechanism‐based methods with reasonable assumptions would be critical for the successful prediction of a clinically effective dose in the preclinical stage of drug development.

项与 Brezivaptan 相关的新闻（医药）

2022-12-04

·药渡Daily

2022.11.19-11.25全球药物研发进展

1全球新药研发进展2022.11.19-11.25这一周，全球新药研发各个领域均有新的突破，包括：肿瘤、精神、神经、消化系统、心血管、感染、免疫、皮肤和结缔组织疾病、内分泌系统等多个领域。其中，肿瘤等热门领域依旧同时涵盖了化学药、生物药、细胞疗法的最新研究进展。Telix放射性核素偶联药物（RDC）TLX101 IPAX-Linz II期临床研究完成首例患者给药2022年11月22日，Telix宣布，放射性核素偶联药物（RDC）TLX101联合外照射放疗的IPAX-LinzII期临床研究完成首例患者给药，用于治疗复发性高级别脑胶质瘤（HGG），包括多形性胶质母细胞瘤。TLX101（4-L-[131I] iodo-phenylalanine，或131I-IPA）是Telix的主要治疗临床项目之一，并已在美国和欧洲获得孤儿药认定。TLX101靶向L型氨基酸转运蛋白1（LAT-1），这些蛋白通常在许多恶性肿瘤（包括HGG/GBM）中过度表达。IPAX-Linz研究由奥地利林茨开普勒大学医院的Josef Pichler教授领导，以IPAX-1研究中产生的数据为基础。2022年9月报告的IPAX-1研究的最终结果显示出良好的安全性和积极的初步治疗效果。IPAX-Linz将继续研究TLX101对欧洲领先的神经肿瘤学站点的二线难治性患者的益处。本研究针对10名患者的招募，目标是收集有关临床效用的其他数据。IPAX-Linz将与IPAX-2同时运行，IPAX-2正在评估TLX101与新诊断（一线）GBM患者中由EBRT和替莫唑胺组成的术后护理标准。来源：Telix官网EmbarkNeuro宣布启动ANC-501的II期临床试验2022年11月21日，EmbarkNeuro宣布，ANC-501的II期临床试验已完成首例患者给药。ANC-50是EmbarkNeuro开发的“First-in-clas”首创加压素1b（V1b）受体拮抗剂，用于用治疗重度抑郁症（MDD）。这项多中心、开放标签II期临床试验旨在评估口服ANC-50150mg在8周内的安全性、耐受性和有效性。该试验将招募18-65岁目前患有抑郁症且标准治疗无效、基线皮质醇水平升高的中度至重度MDD患者。主要疗效终点是使用蒙哥马利-奥斯伯格抑郁评定量表（MADRS）总分在治疗8周结束时与基线相比的变化。参与者将在完成给药后再进行8周的安全性评估。有关试验的更多信息，请访问www.clinicaltrials.gov（NCT05439603）。来源：EmbarkNeuro官网2022.11.19-11.25全球新药研发进展（部分）更多具体信息，请联系小编获取2国内新药研发进展2022年11月19日-11月25日，国内新药研发同样突飞猛进，治疗肿瘤的生物药进展迅速。KN026二线治疗HER2表达胃癌或胃食管结合部癌研究结果在国际知名期刊EJC发表2022年11月23日，康宁杰瑞与石药集团共同宣布，HER2双抗KN026二线治疗HER2表达晚期胃癌或胃食管结合部癌的II期临床研究结果在国际肿瘤领域知名期刊《European Journal of Cancer》（EJC，最新影响因子10.002）上发表。中国人民解放军总医院第五医学中心徐建明教授为该文第一作者。•KN026是一种人表皮生长因子受体2（HER2）双特异性抗体，可以作用于HER2不同细胞外结构域II和IV；• KN026二线治疗HER2高表达胃癌或胃食管结合部癌提高了客观缓解率；• KN026具有克服曲妥珠单抗耐药性的巨大潜力；• KN026表现出了良好的安全性。本研究是一项单臂、开放、多中心的II期临床试验（KN026-202），入组既往至少接受过一线治疗的晚期胃及胃结合部腺癌患者，根据中心实验室检测结果分为HER2高表达（队列1:IHC3+或IHC2+且ISH+）和低表达（队列2:IHC1+，或IHC2+ ISH-，或IHC 0且ISH+）两个队列，旨在评估KN026在这两个队列中的疗效。本研究共入组了45例患者，其中27例HER2高表达患者分别接受KN026 10mg/kg QW（5例）、 20mg/kg Q2W（4例）、30mg/kg Q3W（18例）治疗。27例HER2高表达患者中，有近一半的患者（41%）既往接受过≥2线治疗，约60%的患者既往接受过曲妥珠单抗治疗。25例患者接受过至少一次肿瘤影像学评估，其中14例评估为部分缓解（PR），5例评估为疾病稳定（SD）,5例评估为疾病进展（PD），1例无法评估，客观缓解率（ORR）高达56%，且能够获得长期的疾病缓解，中位缓解持续时间（DOR）为9.7个月，中位PFS和OS分别高达8.3个月和16.3个月。对于既往接受过曲妥珠治疗后进展的14例患者，仍然有优异的治疗效果。45例患者全部纳入安全性分析，常见药物相关不良事件（TRAE）为AST升高（27%）、ALT升高（20%）、皮疹（16%）、贫血（16%）和输液相关反应（16%），主要为轻到中度（CTCAE 1-2级），仅4例（8.9%）患者发生了CTCAE 3级TRAE，无患者发生CTCAE 4级及导致死亡的TRAE。研究结果显示，KN026在HER2高表达胃癌/胃食管结合部癌患者中具有优异疗效和良好的安全性。目前，KN026联合化疗治疗HER2阳性胃癌（包括胃-食管结合部腺癌）的注册临床研究正在顺利进行中，评估用于一线治疗失败的HER2阳性胃癌（包括胃-食管结合部腺癌）的有效性和安全性。胃癌及胃食管结合部腺癌是常见的恶性肿瘤之一，全球每年胃癌新发病例超过100万例，中国是胃癌高发国家，每年新发约41万例，死亡约29.4万例，新发和死亡病例均占全世界胃癌病例的40%以上。我国胃癌的特点是早期胃癌发现率低，5年生存率低（约35.1%），严重威胁国人的生命健康。HER2在很多肿瘤中都存在过表达，其中胃癌约15-20%，HER2过表达与肿瘤侵袭性以及不良预后有关，因此在经一线治疗后进展或复发的HER2阳性胃癌患者，存在着巨大的尚未满足的临床需求。随着靶向治疗的发展，HER2阳性的晚期胃癌在联合使用靶向药物治疗后，相比传统化疗方案有更好的疗效。来源：康宁杰瑞公告开拓药业宣布完成全球首个外用PROTAC(GT20029)I期临床试验2022年11月24日，开拓药业公布其自主研发的新型靶向雄激素受体（AR）的蛋白降解嵌合体（PROTAC）化合物GT20029治疗雄激素性脱发（AGA）和痤疮的中国I期临床试验积极结果，显示其在健康受试者中具有良好的安全性、耐受性和药代动力学特征。GT20029是全球首个完成I期临床试验的外用PROTAC化合物。临床前研究显示，GT20029通过降解AR蛋白，从而有效阻断AR信号通路激活导致的毛囊萎缩微型化作用，抑制毛发变细、变软和脱落，并且能够有效地抑制皮脂腺发育与皮脂分泌。GT20029仅在局部产生疗效，通过限制皮肤渗透从而减少全身药物暴露，以获得更好的安全性。对二氢睾酮（DHT）诱导的小鼠模型药效学研究的重复结果表明，GT20029可显著减少脱发，且有统计学差异。此外，对丙酸睾酮（TP）诱导的金黄地鼠皮脂腺斑痤疮模型药效学研究的结果表明，GT20029可显著抑制皮脂腺斑的增大，且有统计学差异。该项在中国开展的I期临床试验，由复旦大学附属华山医院I期临床研究中心张菁教授和武晓捷副教授担任主要研究者（PI），是一项随机、双盲、安慰剂对照研究，以评估GT20029（凝胶和酊）外用局部给药的安全性和药代动力学等特征。本试验分别在健康受试者中进行GT20029（凝胶和酊）的单、多剂外用给药。该项I期临床数据显示，92名受试者接受了至少一剂试验用药，其中68名受试者接受凝胶，24名受试者接受酊剂。GT20029作为外用药在健康受试者中安全性和耐受性良好，人体药物浓度暴露水平低。单次用药后，所有受试者均无体内药物暴露量，所有剂量组的所有样品血药浓度均低于定量下限（LLOQ，0.001ng/mL）。连续14天用药后，各剂量组最大血药浓度均值均在0.05ng/mL以下。试验期间发生的与研究药物相关的不良事件（TRAE）均为1级，没有发生1级以上的TRAE。GT20029是开拓药业基于PROTAC技术开发的外用化合物。2021年4月，中国国家药品监督管理局（NMPA）批准GT20029开展临床试验。2022年8月，GT20029中国I期临床试验完成受试者入组给药。2021年7月，GT20029获得美国食品药品监督管理局（FDA）的I期临床试验许可。2022年10月，GT20029美国I期临床试验完成受试者入组给药。来源：开拓药业官网2022.11.19-11.25国内新药研发进展（部分）更多具体信息，请联系小编获取3国内临床默示许可进展2022.11.19-11.25临床默示许可进展（部分）更多具体信息，请联系小编获取4全球医药交易事件Prothena与诺和诺德就ATTR心肌病药物PRX004/NNC6019达成收购协议2022年11月21日，Prothena宣布，公司和诺和诺德就NNC6019（前身为PRX004）达成全面收购协议，并从诺和诺德获得4000万美元的里程碑付款。根据协议条款，Prothena有资格在实现多个临床开发和销售里程碑后获得高达12亿美元的资金，包括迄今为止赚取的1亿美元。自2021年7月初步协议后，诺和诺德获ATT淀粉样变性业务和管线的知识产权和相关权利的全球全部权利。NNC6019（以前称为PRX004）是一种研究性抗体，旨在去除与遗传性和野生型ATTR淀粉样变性疾病病理学相关的淀粉样蛋白，而不会影响蛋白质的天然正常四聚体形式。NNC6019提出的作用机制是消耗沉积的淀粉样蛋白以改善器官功能和循环非天然TTR以防止进一步的器官沉积。在临床前研究中，PRX004显示出抑制淀粉样纤维形成，结合非天然TTR的可溶性聚集体形式以及通过抗体介导的吞噬作用促进不溶性淀粉样纤维清除的能力。这种差异化的耗竭作用机制可以开发为ATTR淀粉样变性的单一治疗方法，也可以补充现有的治疗方法，以稳定或减少天然TTR四聚体的产生。来源：Prothena官网安酷生物与JLP Health达成获得胶质母细胞瘤创新疗法技术转移和商业授权协议2022年11月23日，安酷生物技术（苏州）有限公司通过协议授权的方式，从奥地利JLP Health公司获得胶质母细胞瘤创新疗法在中国地区的独家开发和商业化权益，与此相关的所有研究数据和知识产权都于近期转移到安酷生物。胶质母细胞瘤（GBM）是最具侵袭性的原发性脑肿瘤之一，对新的有效药物存在很大的市场需求，据估计中国每年新增4万至5万名患者。尽管通过手术、化疗和放射治疗能取得一定疗效，但患者的中位生存期仅为12至15个月，而且在一线标准治疗后几乎不可避免地进展或复发，5年相对存活率仅有6.8%。因此这一领域迫切需要更有效的创新性药物治疗方案。此次由奥地利生物技术公司JLP Health向安酷生物转移的小分子药物联合疗法，是基于该公司研发团队独立开发的基于单倍体细胞的独特筛选技术（该项技术之前已经转移到安酷生物应用于抗肿瘤和抗病毒药物的独立开发）和中国传统中药资源的结合。JLP Heath研发团队应用独特的靶点筛选技术解析了来源于传统中药所熟知的天然化合物青蒿素的抗肿瘤活性机理。基于巧妙且合理的实验设计，青蒿素与其它活性增强剂小分子化合物进行联合用药用于脑瘤的治疗。在人造大脑癌症模型以及病人耐受性脑癌细胞模型的临床前研究中，这种联合疗法对脑瘤有非常好的治疗效果，但对正常脑组织细胞却没有明显影响。这种联合用药的有效性在胶质母细胞瘤的临床前动物模型中得到进了一步证实，其中甚至有肿瘤症状的完全缓解。基于这些积极的结果，这种联合疗法将在2023年进入临床开发阶段。来源：安酷生物官网2022.11.19-11.25全球医药交易（部分）更多具体信息，请联系小编获取▲编辑：胡桃声明：药渡数据出品，未经允许禁止转载👇欢迎关注药渡数据媒体矩阵

临床2期孤儿药临床结果

2022-11-22

·PRNewswire

EmbarkNeuro Announces Initiation of Phase 2 Trial of ANC-501, a First-In-Class, V1b Receptor Antagonist for the Personalized Treatment of Depression

VILLANOVA, Pa. and OAKLAND, Calif., Nov. 21, 2022 /PRNewswire/ -- EmbarkNeuro, a neuroscience-focused biotech company formerly known as Ancora Bio that was founded in 2021 by the venture firm Aditum Bio, today announced that the first patient has been dosed in its Phase 2 trial of ANC-501, a first-in-class vasopressin 1b (V1b) receptor antagonist for the treatment of major depressive disorder (MDD). This 8-week single-arm trial will assess the efficacy of ANC-501 when added to a standard antidepressant therapy in patients with biomarker-confirmed disruption in their stress-response system. "Rates of depression and anxiety have risen dramatically since the advent of the COVID-19 pandemic, which has spurred extreme stress due to social isolation and exacerbated health concerns," said Stephen Kanes M.D., Ph.D., Chief Executive Officer of EmbarkNeuro. "As people with a history of adverse childhood experiences, toxic stress or HPA axis disruption have been the hardest hit, it is more important than ever to rethink all aspects of mental health interventions and create targeted treatments with underlying conditions in mind for patients not responsive to standard therapies. We look forward to advancing ANC-501 and providing patients with depression and measurable disruption of their HPA axis with a treatment option. Our new name, EmbarkNeuro, represents our enthusiasm as we embark on the exploration of new pathways for the treatment of brain health disorders." The multi-center, open-label Phase 2 clinical trial is designed to evaluate the safety, tolerability, and efficacy of orally administered ANC-501 50mg over 8 weeks. The trial will enroll individuals aged 18-65 who are currently depressed and for whom standard treatments have not been effective. Patients with moderate to severe MDD who have confirmed baseline cortisol level elevations are eligible to participate. The primary efficacy endpoint is change from baseline at the end of 8 weeks of treatment using the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Participants will be followed for safety assessments for an additional 8 weeks following completion of dosing. For more information about the trial, please visit www.clinicaltrials.gov (identifier NCT05439603). A double-blind placebo-controlled trial of ANC-501 in patients with depression is planned for 2023 based on the outcome of this initial Phase 2 trial. ANC-501 is an investigational compound and not approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. About Major Depressive Disorder (MDD) Major depressive disorder (MDD) is a common condition affecting over 20 million U.S. residents annually causing social, occupational, and educational impairment, along with depressed mood or loss of interest or pleasure in daily activities. The hypothalamic-pituitary-adrenal (HPA) axis plays a critical role in managing the body's response and adaption to stress. The peptide hormone vasopressin acting through the vasopressin 1b (V1b) receptors is a key regulator of the body's stress response. About EmbarkNeuro EmbarkNeuro, formerly known as Ancora Bio, is focused on bringing important new personalized treatments to patients with mental health disorders. Rates of major depression are rapidly rising, much of this attributable to the dramatic increase in stress brought on by the COVID-19 pandemic. The company is identifying depressed individuals with a potential biomarker linked to the stress response system (elevated cortisol) and developing ANC-501 as a new treatment specifically for these patients. For more information about EmbarkNeuro, please visit https://embarkneuro.com/.

临床2期

2021-06-30

·Endpoints

Joe Jimenez and Mark Fishman sign up their 5th drug candidate — and they have another big target in their crosshairs

Ex-Novartis chief Joe Jimenez and his longtime colleague Mark Fishman have now ramped up their 5th biotech sub at the upstart Aditum. And once again, they’re tackling a big, tough market. The new outfit is called Ancora Bio, and its drug is a selective vasopressin 1b receptor — V1b — antagonist from Taisho Pharmaceutical that will roll ahead under a new code name: ANC-501. Evidently this is the same depression drug that Taisho tested in a recent Phase II clinical study. Some numbers trended in its favor compared to a placebo but fell short of statistical significance — just one in a long series of failures for major depression.

100 项与 Brezivaptan 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
重度抑郁症	临床1期	美国	Taisho Pharmaceutical R&D, Inc.	2017-07-03
焦虑症	药物发现	日本	Taisho Pharmaceutical Co., Ltd.	-
抑郁症	药物发现	日本	Taisho Pharmaceutical Co., Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05439603 (CTgov)	临床2期	重度抑郁症	15	ANC-501	齋觸蓋襯遞獵衊鹹襯壓(鑰膚鹹積構齋膚網壓觸) = 鹹糧窪壓艱鑰窪選窪襯網夢顧觸繭積鹹鹹觸鏇 (獵蓋襯淵膚簾製餘選衊, 窪餘築繭積淵鹽鑰糧糧 ~ 製餘製鏇積鬱簾艱鹹鹹) 更多	-	2024-12-31
NCT03093025 (CTgov)	临床2期	重度抑郁症	51	TS-121 10 mg (TS-121 10mg)	(築醖製餘構蓋網窪選憲) = 構構積製鏇膚齋壓艱鬱獵願築糧鑰夢憲積鹽膚 (夢選獵積鏇製範糧膚醖, 網顧顧範窪衊鹹窪蓋廠 ~ 膚鏇鏇壓艱構積醖鑰夢) 更多	-	2019-12-09
NCT03093025 (CTgov)	临床2期	重度抑郁症	51	TS-121 50 mg (TS-121 50mg)	(築醖製餘構蓋網窪選憲) = 壓鏇衊積鏇築築淵願顧獵願築糧鑰夢憲積鹽膚 (夢選獵積鏇製範糧膚醖, 餘簾襯醖築鹹網簾積鬱 ~ 願鬱製遞顧簾顧積顧艱) 更多	-	2019-12-09